David Paul Richman, M.D.
Specialties
Neurology - Neuroimmunology, Myasthenia Gravis
Department
Title
- Distinguished Professor
Reviews
UC Davis Midtown Ambulatory Care Center
3160 Folsom Blvd, Suite 2100
Sacramento, CA 95816
Driving Directions
Primary Phone:
916-734-3588
Additional Phone Numbers
Clinic Fax: 916-734-7188
Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Philosophy of Care
Dr. Richmand approaches his practice with 3 main goals to be: evidence-based, collaborative, and straight-forward.
Clinical Interests
David P. Richman's professional interests include biochemistry and pharmacology of the nicotinic acetylcholine receptor and muscle-specific kinase (MuSK), diseases of neuromuscular transmission, myasthenia gravis, anti-MuSK myastemia, and Lambert-Eaton myasthenic syndrome, and the pathogenesis and control of autoimmune response in myasthenia gravis. Richman has coauthored an extensive list of publications and book chapters on neurological disease and related topics.
Research/Academic Interests
Dr. Richman studies the biological mechanisms that underlie diseases of the neuromuscular junction with the goal of improving their treatment. He primarily develops animal models of the diseases and test new treatments in this setting. He also assists in clinical trials of these new treatments.
Division
Neurology
Center/Program Affiliation
Education
M.D., Johns Hopkins University School of Medicine, Baltimore MD 1969
A.B., Princeton University, Princeton NJ 1965
Internship: Internal Medicine, Albert Einstein College of Medicine, New York City NY 1969-1970
Residency
Internal Medicine, Albert Einstein College of Medicine, New York City NY 1970-1971
Neurology, Resident and Chief Resident, Massachusetts General Hospital, Boston MA 1971-1974
Fellowships
Neuroimmunology, Harvard Medical School, Boston MA 1974-1976
Board Certifications
American Board of Psychiatry and Neurology - Neurology,
Professional Memberships
American Academy of Neurology
American Association of Immunologists
American Neurological Association
Association of California Neurologists
International Society of Neuroimmunologists
Honors and Awards
UC Davis Distinguished Professor, 2017
Fellow, American Academy of Neurology, 2017
Conquer Award for Myasthenia Gravis Research, Myasthenia Gravis Foundation of Illinois, 2002
Muscular Dystrophy Association, Post-Doctoral Fellowship, 1975, 1976
Kermit Osserman Post-Doctoral Fellowship, Myasthenia Gravis Foundation, 1974, 1975
Henry Viets Student Fellowship, Myasthenia Gravis Foundation, 1968
University Scholar, Princeton University, 1962, 1963, 1964, 1965
Select Recent Publications
Nowak RJ, Coffey CS, Goldstein JM , Dimachkie MM, Benatar M, Kissel JT, Wolfe GL, Burns T, Freimer ML, Nations S, Granit V, Smith AG, Richman DP, Ciafaloni E, Al-Lozi M, Sams, Quan D, Ubogu E, Pearson B, Sharma A, Yankey JW, Uribe L, Shy ME, Amato AA, Conwit R, O’Connor KC, Hafler DA, Cudkowicz, ME, Barohn RJ, and the NeuroNEXT NN103 BeatMG Study Team. B-cell Targeted Treatment in Myasthenia Gravis (BeatMG Study): A Phase 2 Randomized Trial of Rituximab. Submitted JAMA Neurology. 2020.
Borges LS, Richman DP. Muscle-Specific Kinase Myasthenia Gravis. Front Immunol. 2020;11(707):1-11. PMID: 32457737
Lara MS Afify A, Ellis MP, Phan CT, Richman DP, Riess. Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma. Clinical Lung Cancer. 2019;20(4):e489-e491. PMID: 31085042.
Sanders DB, Juel VC, Harati Y, Smith AG, Peltier AC, Marburger T, Lou JS, Pascuzzi RM, Richman DP, Xie T, Demmel V, Jacobus LR, Aleš KL, Jacobus DP, Dapper Study Team. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia. Muscle Nerve. 2018;57(4):561-568. PMID: 29280483.
Bissig D, Manjunath R, Brittany R, Traylor R, Richman DP and Ng KL. Acute stroke despite dabigatran anticoagulation treated with idarucizumab and intravenous tissue plasminogen activator. J Stroke Cerebrovasc Dis. 2017:e102-e104. [Epub ahead of print] PMID: 28416406.
Richman DP. Lrp4 antibodies in myasthenia gravis: Pathogenic or protective. European J Neurol. 2016;23(11):1593-1594. PMID: 27753233.
Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87(4):419-25. PMID: 27358333.
Renton AE, Pliner HA, Carlo Provenzano et al. A genome-wide association study of myasthenia gravis. JAMA Neurol. 2015;72:396-404.
Oskarsson B, Rocke DM, Dengel K, Richman DP. Myasthenia gravis exacerbation after discontinuing mycophenolate: A single center cohort study. Neurology. 2016;86(12):1159-63. PMID: 26850977.
Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM Jr, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM Jr, Hehir MK, Hobson-Webb LD, Howard JF Jr, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve. 2016 Feb;53(2):165-8.
The Huntington Study Group PHAROS Investigators. Clinical-Genetic Specificity in the Prospective Huntington At-Risk Observational Study (PHAROS): implications for clinical trials. JAMA Neurol. 2016;73(1):102-10.